(Q38733474)

English

The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions

scientific article published on 11 February 2016

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

0 references

Michael A. Nauck

1

object named as

Michael A Nauck

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

author name string

Juris J Meier

2

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

publication date

11 February 2016

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

The Lancet: Diabetes & Endocrinology

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

525-536

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The incretin concept today

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Gastric inhibitory polypeptide: the neglected incretin revisited

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide 1(GLP-1) in biology and pathology

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced Incretin Effect in Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

On the treatment of Diabetus mellitus by acid extract of Duodenal Mucous Membrane

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of DPP-4 with Vildagliptin Improved Insulin Secretion in Response to Oral as well as “Isoglycemic” Intravenous Glucose without Numerically Changing the Incretin Effect in Patients with Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Incretin and islet hormonal responses to fat and protein ingestion in healthy men.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Dissociated incretin hormone response to protein versus fat ingestion in obese subjects

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Incretin effect after oral amino acid ingestion in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Contributions of fat and protein to the incretin effect of a mixed meal.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Incretin-based therapies: where will we be 50 years from now?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

β-cell function, incretin effect, and incretin hormones in obese youth along the span of glucose tolerance from normal to prediabetes to type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Gastric inhibitory polypeptide (GIP) release and incretin effect after oral glucose in obesity and after jejunoileal bypass

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Electronimmunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) im man

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Regulation of Intestinal Proglucagon- Derived Peptide Secretion by Intestinal Regulatory Peptides*

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Brain glucose sensing and neural regulation of insulin and glucagon secretion

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Preserved incretin effect in type 1 diabetic patients with end-stage nephropathy treated by combined heterotopic pancreas and kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Impaired regulation of the incretin effect in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The incretin effect in Korean subjects with normal glucose tolerance or type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Incretin effect and glucagon responses to oral and intravenous glucose in patients with maturity-onset diabetes of the young--type 2 and type 3.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Normal secretion of the incretin hormones glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 during gestational diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Causes of type 2 diabetes in China

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Postpartum reversibility of impaired incretin effect in gestational diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Incretin Effect in Women with Former Gestational Diabetes within a Short Period after Delivery

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Steroid-induced insulin resistance and impaired glucose tolerance are both associated with a progressive decline of incretin effect in first-degree relatives of patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Functional assessment of pancreatic beta-cell area in humans

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of glycemia on plasma incretins and the incretin effect during oral glucose tolerance test

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The impact of dipeptidyl peptidase 4 inhibition on incretin effect, glucose tolerance, and gastrointestinal-mediated glucose disposal in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Bariatric surgery versus intensive medical therapy in obese patients with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Magnitude and variability of the glucagon-like peptide-1 response in patients with type 2 diabetes up to 2 years following gastric bypass surgery

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Regulation of gastric emptying rate and its role in nutrient-induced GLP-1 secretion in rats after vertical sleeve gastrectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparable early changes in gastrointestinal hormones after sleeve gastrectomy and Roux-En-Y gastric bypass surgery for morbidly obese type 2 diabetic subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

GLP-1 and glucose tolerance after sleeve gastrectomy in morbidly obese subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

First-phase insulin secretion, insulin sensitivity, ghrelin, GLP-1, and PYY changes 72 h after sleeve gastrectomy in obese diabetic patients: the gastric hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Laparoscopic sleeve gastrectomy versus single anastomosis (mini-) gastric bypass for the treatment of type 2 diabetes mellitus: 5-year results of a randomized trial and study of incretin effect

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Lower ghrelin levels and exaggerated postprandial peptide-YY, glucagon-like peptide-1, and insulin responses, after gastric fundus resection, in patients undergoing Roux-en-Y gastric bypass: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Recovery of the incretin effect in type 2 diabetic patients after biliopancreatic diversion.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Dissociated incretin response to oral glucose at 1 year after restrictive vs. malabsorptive bariatric surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of Roux-en-Y gastric bypass on energy and glucose homeostasis are preserved in two mouse models of functional glucagon-like peptide-1 deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

GLP-1 action and glucose tolerance in subjects with remission of type 2 diabetes after gastric bypass surgery

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

GLP-1 plays a limited role in improved glycemia shortly after Roux-en-Y gastric bypass: a comparison with intensive lifestyle modification

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Bile Acids Trigger GLP-1 Release Predominantly by Accessing Basolaterally Located G Protein-Coupled Bile Acid Receptors

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Systemic bile acid sensing by G protein-coupled bile acid receptor 1 (GPBAR1) promotes PYY and GLP-1 release

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Gut microbiota and GLP-1.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Alteration of gut microbiota by vancomycin and bacitracin improves insulin resistance via glucagon-like peptide 1 in diet-induced obesity

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900482-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2213-8587(15)00482-9

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38733474&oldid=2249880015"